TO · APLI.TO
Appili Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Halifax, NS B3H 0A8
- Website
- appilitherapeutics.com
Price at previous close
$0.02
Market cap 2.57M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $1.13 | ||||
| 2021 | $0.85 | $28.68 | |||
| 2022 | $0.07 | $0.00 | $0.00 | ||
| 2023 | $0.04 | $33.13 | $0.00 | $0.00 | $5.25 |
| 2024 | $0.04 | $43.81 | $142.11 | $0.00 | $0.00 |
| 2025 | $0.01 | $38.07 |
About Appili Therapeutics Inc.
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
- CEO
- Donald D. Cilla Jr. Pharmd
- Employees
- 8
- Beta
- -0.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.00 ÷ $0.02) − 1 = -100% (DCF, example).